p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., Tinsley, R., Eng, M., Wilczynski, S., Ellenhorn, J. D. I., Diamond, D. J., Cristea, M.
The American Association for Cancer Research (AACR)
Published 2018